Vestibular DisorderNCT04905472
Vestibular Implants Tested in Human Subjects
A study testing Vestibular prosthesis/implant and Vestibular Implant Stimulation in people with Vestibular Disorder and Vestibular Ataxia, run by Massachusetts Eye and Ear Infirmary at 3 sites in 2 countries.
Trial summary
The goal of this study is to improve the vestibular implant's ability to reduce the vestibular-dependent perceptual, postural, and visual symptoms that affect patients with severe peripheral vestibular damage. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Vestibular Disorder, Vestibular Ataxia, Vestibular Loss, Bilateral
- What is being tested?
- Vestibular prosthesis/implant and Vestibular Implant Stimulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 3 sitesin 2 countries
- Study dates
- 1 Aug 2019to 31 Jan 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- scheduled for cochlear implant CI surgery because of deafness
- minimum of five year history of documented absence of auditory \& vestibular function, based on review of their audiograms \& vestibular tests
- Specific vestibular criteria are: peak ice water caloric response of less than 3 deg/s for each ear; yaw VOR time constant < 3.0 sec and gain < 0.25; and reduced head impulse gain (<0.25) for all canal planes.
- Specific audiographic criteria: 80dB or greater sensorineural hearing loss in both ears
Who cannot join
- pregnant
- not scheduled for cochlear implant/vestibular implant surgery
- unable to walk 50m
- other neurological disorder (other than migraine), otologic disease (other than presbycusis)
Trial locations and contacts
3 sites in 2 countries.
3 sites in 2 countries
United States2 sites
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts, 02114
Ohio State University
Columbus, Ohio, 432120000
Switzerland1 site
Universite de Geneve Hospital (UNIGE)
Geneva, 1211- CH-0
About this study
The goal of this study is to improve the vestibular implant's ability to reduce the vestibular-dependent perceptual, postural, and visual symptoms that affect patients with severe peripheral vestibular damage. The long-term research plan is focused on exploring the three questions which must be answered to assess the clinical utility of a vestibular implant (VI) in vestibulopathic patients - i) how can information transfer from the VI sensors to the brain be optimized; ii) how does the three-dimensional angular velocity information provided by the VI interact in the brain with other sensorimotor (vision, otolith, efferent) signals; and iii) how effectively does the VI alleviate the behavioral deficits and subjective symptoms experienced by patients with severe vestibular damage. The current study will be used to focus on two key subsets of these questions. Over one year, the investigators will study approximately 5 patients who have severe bilateral vestibular damage and functioning VI's, which will focus on aim 1: how the angular velocity information sensed by the VI can be optimally transferred to the brain; and aim 2: how effectively the VI improves the clinical status of vestibulopathic patients when they receive acute and sub-acute (3 days) motion-modulated stimulation. In sum, the investigators aim to improve the efficacy of the VI in human subjects by developing new knowledge about how the brain processes motion cues provided by the VI and correlating this information with behavioral outcomes.
Read the detailed description
Aim1: Optimizing information transfer from the VI to the brain: the investigators will study two approaches - altering the transfer function that relates the head's angular velocity to the electrical stimulation applied by the VI to the canal ampullary nerves; and utilizing the VI's unique capability to add noise to vestibular afferents. Regarding the former, the study team plans to initiate investigation of the principal components of the transfer function by testing the VI's capabilities when - the baseline resting stimulation rate is modified up or down; the temporal filtering (e.g., corner frequency of the high-pass filter) of the angular velocity signal recorded by the rate sensor is modified; the slope of the linear component of the hyperbolic tangent function that relates filtered head velocity to stimulation strength is altered; and different modes of stimulation modulation are used to encode head velocity (e.g, modifying the amplitude, the rate, or co-modulating the amplitude and rate of the current pulses). Regarding the use of noise, the investigators will test a given transfer function with different amplitudes of broad-band white electrical noise superimposed on the stimulation that encodes angular velocity, to determine if information transfer can be improved from the VI to the brain with low-level noise via stochastic resonance, as has been demonstrated in other sensory systems. To determine the efficacy of these approaches, the study team will measure the three basic vestibular-mediated behaviors (eye movements, posture, and perception). In particular we will focus on the amplitude and threshold of the angular vestibulo-ocular reflex (VOR), yaw-axis perceptual thresholds, and postural sway thresholds and amplitude, with the goal of defining the transfer function and noise level that minimizes thresholds (e.g., optimizes the signal-to-noise ratio) and maximizes the amplitude of the behavioral responses. One corollary of these studies is to examine if the different behavioral pathways are optimized with different stimulus parameters, as is suggested by the preliminary data.
Aim 2: Characterizing the effects of VI stimulation on clinical status: Vestibular-mediated behaviors are crucial to patient wellbeing and are degraded after severe vestibular damage. The investigators will initiate the assessment of the VI's clinical utility by quantifying the VOR, posture/gait, and perception using paradigms that isolate the VI's contributions to these behaviors (e.g., VOR during yaw-axis rotation) or paradigms that recapitulate normal activities such as self-generated walking, which require the brain to synthesize the angular velocity information provided by the VI with other sensorimotor cues. The investigators will study these vestibulopathic patients before the VI is activated ('pre'), one hour after activation ('acute,' which allows participants adequate time to adapt to the tonic VI stimulation), and then daily for three days while motion-modulated stimulation is provided by the VI during normal activities ('chronic'). The investigators will also have participants complete several questionnaires prior to stimulation and again in the acute and chronic stimulation states to quantify their subjective responses to VI stimulation. These will include questionnaires that characterize the severity of subjective dizziness and imbalance (Dizziness Handicap Inventory [DHI], Activities Specific Balance Confidence Scale [ABC]); oscillopsia (the Oscillopsia Functional Impact Scale); and a more general quality of life measurement (the Short Form-36 Health Survey). These questionnaires will be modified so they reflect current levels of symptomatology, since the study team will be capturing changes over a short time-frame. The investigators expect that behavior and symptoms will improve during the period of motion-modulated stimulation such that measurements and subjective reports in the 'chronic' stimulation state will be closer to normal than during the 'acute' or 'pre' stimulation states. More complex behaviors (e.g. balance while walking, ABC scores) are predicted to improve more slowly than behaviors that rely on isolated angular velocity cues (e.g., yaw axis VOR, oscillopsia scores). In sum, this study will provide a solid foundation to build upon for future research in which the investigators will further examine the clinical utility of the VI.
- Being tested
- Vestibular prosthesis/implant, Vestibular Implant Stimulation
- Keywords
- eye movements, perception, vestibular, dizziness, sensory integration, prosthesis
- Medical subject headings
- Vestibular Diseases, Bilateral Vestibulopathy, Dizziness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Vestibular prosthesis/implantDevice
The intervention is a vestibular prosthesis which our collaborators at the University of Geneva are implanting into the inner ear in deaf patients without vestibular function who are receiving a cochlear implant. The vestibular implant (VI) has three rate sensors and senses angular head velocity in three dimensions and provides this information to the brain by stimulation the afferent nerves innervating the three semicircular canals. Our goal is to use the VI to better understand how the brain processes this prosthetic information and uses it to generate meaningful behavioral responses including eye movements, postural control, and perception.
Vestibular Implant StimulationDevice
VI subjects will be studied before the implant is activated (pre) and then after it is turned on (acute On); this will take about 2 hrs. Then they will have 8 hours of motion-modulated VI stimulation while they actively explore the hospital environment, after studies will be repeated (chronic On). Each set of outcome experiments will be performed twice, once with and once without low-levels of stochastic noise added to the VI stimulation provided for the 8-hour period. The noise amplitude is tailored to each patient to maximize stochastic resonance so extraction \& integration of spatial signal provided by the VI will always be the first experiment, but the order of the subsequent outcome sessions (active/passive head rotations, tilt/translation motion discrimination and VOR behavioral changes \& postural control) will be randomized. VI subjects will participate in 4 full-day sessions, each separated by at least a month.
| Study group | Role | What they receive |
|---|---|---|
| Vestibular & Cochlear Implant Patients | Experimental | * scheduled for CI surgery because of deafness
* a minimum of five year history of documented absence of auditory and vestibular function, based on review of their audiograms and vestibular tests.
* Specific vestibular criteria are: peak ice water caloric response of less than 3 deg/s for each ear; yaw VOR time constant < 3.0 sec and gain < 0.25; and reduced head impulse gain (<0.25) for all canal planes.
* Specific audiographic criteria: 80dB or greater sensorineural hearing loss in both ears Receives: Device: Vestibular prosthesis/implant; Device: Vestibular Implant Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in Postural Sway Thresholds
Changes in threshold for postural sway, measured using IMUs (inertial measurement unit) placed on the upper back, head, and torso, will be assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following motion-modulated stimulation.
Measured: 3 days
Changes in Postural Sway Amplitudes
Changes in amplitude in postural sway, measured using IMUs (inertial measurement unit) placed on the upper back, head, and torso, will be assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following motion-modulated stimulation.
Measured: 3 days
Changes in Gait dynamics
Changes in gait dynamics, measured using IMUs (inertial measurement unit) placed on the upper back, head, each ankle, and torso during various physical therapy walking tasks (Functional Gait Analysis), will be assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following motion-modulated stimulation.
Measured: 3 days
Changes in Vestibular Ocular Reflex (VOR) Amplitude
This reflex which moves the eyes in response to head movement and is driven by the sensors in the inner ear. Participants will walk in place while fixating on a cyclopean eye-centered near target (0.5m) and a far target (10m) for 60sec each. A lightweight infrared eye tracker with built in 6 degree of freedom IMU (eyeseecam) will be used to measure eye and head movements together. The amplitude or 'gain' (eye velocity divided by head velocity) is assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. Low gain is associated with impaired VOR.
Measured: 3 days
Changes in Vestibular Ocular Reflex (VOR) Threshold
This reflex which moves the eyes in response to head movement and is driven by the sensors in the inner ear. Participants will wear a lightweight infrared eye tracker with built in 6 degree of freedom IMU (eyeseecam). Investigators will gently rotate the participant about the yaw-axis while measuring eye and head movements together. The velocity threshold for VOR is quantified before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following motion-modulated stimulation.
Measured: 3 days
Changes in motion perception in yaw
Perception of head motion and orientation relative to gravity is measured by a continuous task during yaw rotation where the goal is to keep a light pointing in the direction of the start position/straight ahead. The task requires constant corrections because the light's orientation shifts randomly (based on integrated Brownian noise) and accelerates when a wheel is turned, resulting in overshooting errors. This method, a variant of the Critical Control Task used in humans, is an accurate way to capture perceived head motion. Motion perception during yaw-rotation will be assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation.
Measured: 3 days
Changes in motion perception orientation in roll
Perception of head motion and orientation relative to gravity is measured by a continuous subjective-visual-vertical (SVV) task where the subject uses a small steering wheel to keep a light bar orientated parallel to the perceived earth-vertical. The task requires constant corrections because the light bar's orientation shifts randomly (based on integrated Brownian noise) and accelerates when the wheel is turned, resulting in overshooting errors. This method, a variant of the Critical Control Task used in humans, is an accurate way to capture perceived head orientation. The 'perceived upright' is assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation.
Measured: 3 days
Changes in angular error during a navigation task
Participants will perform a path integration or 'complete the triangle' virtual reality task - angular error of responses is measured before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. Greater angular error and variability of angular error is associated with worse visual-spatial memory.
Measured: 3 days
changes in dizziness handicap index score
Participants will fill out the dizziness handicap index questionnaire before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. It is scored 0 to 100 with high scores indicating greater subjective dizziness and disbalance.
Measured: 3 days
changes in activities-specific balance confidence score
Participants will fill out the activities-specific balance confidence questionnaire before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. It is scored from 0-100% with lower scores showing less confidence in balance and more subjective dizziness.
Measured: 3 days
changes in oscillopsia functional impact scale score
Participants will fill out the oscillopsia functional impact scale before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. It is scored from 0 to 215 in 5 point increments.
Measured: 3 days
changes in reported quality of life
Quality of life will be assessed by participants filling out the short form-36 health survey (scored 0 to 100 points) before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation.
Measured: 3 days
changes in cognitive impairment - visual-spatial function
Cognitive impairment will be assessed by participants completing a neuropsychological test battery with a focus on visual-spatial tasks before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. More errors and time to complete the tasks in the battery are associated with visual-spatial memory and function impairment.
Measured: 3 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2021
- Study start1 Aug 2019
- Primary completion31 Jan 2021
- Study completion31 Jan 2021
Why it stopped: Due to COVID-19 pandemic during the 1year of grant funding (2019-2020), no new patients were implanted with the vestibular prosthetic device and enrolled in this study at the University of Geneva study site.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vestibular DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Sponsor type
- University, hospital or other
- Collaborators
- Ohio State University, University of Geneva, Switzerland
- Responsible party
- Principal investigator, Richard Lewis, Massachusetts Eye and Ear Infirmary
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04905472
- Sponsor's protocol ID
- 2019A008661
- Status last verified
- Jun 2024
- First submitted
- 17 May 2021
- Last updated
- 1 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vestibular Implants Tested in Human Subjects
- ClinicalTrials.gov ID
- NCT04905472
- Acronym / sponsor ID
- 2019A008661
- Keywords
- eye movements, perception, vestibular, dizziness, sensory integration, prosthesis
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Due to COVID-19 pandemic during the 1year of grant funding (2019-2020), no new patients were implanted with the vestibular prosthetic device and enrolled in this study at the University of Geneva study site.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Massachusetts Eye and Ear InfirmaryUniversity, hospital or other
- Collaborators
- Ohio State University, University of Geneva, Switzerland
- Study start
- 1 Aug 2019 (actual)
- Primary completion
- 31 Jan 2021 (actual)
- Study completion
- 31 Jan 2021 (actual)
- First posted
- 27 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to improve the vestibular implant's ability to reduce the vestibular-dependent perceptual, postural, and visual symptoms that affect patients with severe peripheral vestibular damage. The long-term research plan is focused on exploring the three questions which must be answered to assess the clinical utility of a vestibular implant (VI) in vestibulopathic patients - i) how can information transfer from the VI sensors to the brain be optimized; ii) how does the three-dimensional angular velocity information provided by the VI interact in the brain with other sensorimotor (vision, otolith, efferent) signals; and iii) how effectively does the VI alleviate the behavioral deficits and subjective symptoms experienced by patients with severe vestibular damage. The current study will be used to focus on two key subsets of these questions. Over one year, the investigators will study approximately 5 patients who have severe bilateral vestibular damage and functioning VI's, which will focus on aim 1: how the angular velocity information sensed by the VI can be optimally transferred to the brain; and aim 2: how effectively the VI improves the clinical status of vestibulopathic patients when they receive acute and sub-acute (3 days) motion-modulated stimulation. In sum, the investigators aim to improve the efficacy of the VI in human subjects by developing new knowledge about how the brain processes motion cues provided by the VI and correlating this information with behavioral outcomes.
Detailed description
Aim1: Optimizing information transfer from the VI to the brain: the investigators will study two approaches - altering the transfer function that relates the head's angular velocity to the electrical stimulation applied by the VI to the canal ampullary nerves; and utilizing the VI's unique capability to add noise to vestibular afferents. Regarding the former, the study team plans to initiate investigation of the principal components of the transfer function by testing the VI's capabilities when - the baseline resting stimulation rate is modified up or down; the temporal filtering (e.g., corner frequency of the high-pass filter) of the angular velocity signal recorded by the rate sensor is modified; the slope of the linear component of the hyperbolic tangent function that relates filtered head velocity to stimulation strength is altered; and different modes of stimulation modulation are used to encode head velocity (e.g, modifying the amplitude, the rate, or co-modulating the amplitude and rate of the current pulses). Regarding the use of noise, the investigators will test a given transfer function with different amplitudes of broad-band white electrical noise superimposed on the stimulation that encodes angular velocity, to determine if information transfer can be improved from the VI to the brain with low-level noise via stochastic resonance, as has been demonstrated in other sensory systems. To determine the efficacy of these approaches, the study team will measure the three basic vestibular-mediated behaviors (eye movements, posture, and perception). In particular we will focus on the amplitude and threshold of the angular vestibulo-ocular reflex (VOR), yaw-axis perceptual thresholds, and postural sway thresholds and amplitude, with the goal of defining the transfer function and noise level that minimizes thresholds (e.g., optimizes the signal-to-noise ratio) and maximizes the amplitude of the behavioral responses. One corollary of these studies is to examine if the different behavioral pathways are optimized with different stimulus parameters, as is suggested by the preliminary data.
Aim 2: Characterizing the effects of VI stimulation on clinical status: Vestibular-mediated behaviors are crucial to patient wellbeing and are degraded after severe vestibular damage. The investigators will initiate the assessment of the VI's clinical utility by quantifying the VOR, posture/gait, and perception using paradigms that isolate the VI's contributions to these behaviors (e.g., VOR during yaw-axis rotation) or paradigms that recapitulate normal activities such as self-generated walking, which require the brain to synthesize the angular velocity information provided by the VI with other sensorimotor cues. The investigators will study these vestibulopathic patients before the VI is activated ('pre'), one hour after activation ('acute,' which allows participants adequate time to adapt to the tonic VI stimulation), and then daily for three days while motion-modulated stimulation is provided by the VI during normal activities ('chronic'). The investigators will also have participants complete several questionnaires prior to stimulation and again in the acute and chronic stimulation states to quantify their subjective responses to VI stimulation. These will include questionnaires that characterize the severity of subjective dizziness and imbalance (Dizziness Handicap Inventory [DHI], Activities Specific Balance Confidence Scale [ABC]); oscillopsia (the Oscillopsia Functional Impact Scale); and a more general quality of life measurement (the Short Form-36 Health Survey). These questionnaires will be modified so they reflect current levels of symptomatology, since the study team will be capturing changes over a short time-frame. The investigators expect that behavior and symptoms will improve during the period of motion-modulated stimulation such that measurements and subjective reports in the 'chronic' stimulation state will be closer to normal than during the 'acute' or 'pre' stimulation states. More complex behaviors (e.g. balance while walking, ABC scores) are predicted to improve more slowly than behaviors that rely on isolated angular velocity cues (e.g., yaw axis VOR, oscillopsia scores). In sum, this study will provide a solid foundation to build upon for future research in which the investigators will further examine the clinical utility of the VI.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Vestibular & Cochlear Implant Patients | Experimental | Device: Vestibular prosthesis/implant, Device: Vestibular Implant Stimulation* scheduled for CI surgery because of deafness * a minimum of five year history of documented absence of auditory and vestibular function, based on review of their audiograms and vestibular tests. * Specific vestibular criteria are: peak ice water caloric response of less than 3 deg/s for each ear; yaw VOR time constant < 3.0 sec and gain < 0.25; and reduced head impulse gain (<0.25) for all canal planes. * Specific audiographic criteria: 80dB or greater sensorineural hearing loss in both ears |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- scheduled for cochlear implant CI surgery because of deafness
- minimum of five year history of documented absence of auditory \& vestibular function, based on review of their audiograms \& vestibular tests
- Specific vestibular criteria are: peak ice water caloric response of less than 3 deg/s for each ear; yaw VOR time constant < 3.0 sec and gain < 0.25; and reduced head impulse gain (<0.25) for all canal planes.
- Specific audiographic criteria: 80dB or greater sensorineural hearing loss in both ears
Key exclusion criteria (4 listed)
- pregnant
- not scheduled for cochlear implant/vestibular implant surgery
- unable to walk 50m
- other neurological disorder (other than migraine), otologic disease (other than presbycusis)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Vestibular prosthesis/implantThe intervention is a vestibular prosthesis which our collaborators at the University of Geneva are implanting into the inner ear in deaf patients without vestibular function who are receiving a cochlear implant. The vestibular implant (VI) has three rate sensors and senses angular head velocity in three dimensions and provides this information to the brain by stimulation the afferent nerves innervating the three semicircular canals. Our goal is to use the VI to better understand how the brain processes this prosthetic information and uses it to generate meaningful behavioral responses including eye movements, postural control, and perception. | Device | Vestibular & Cochlear Implant Patients |
| Vestibular Implant StimulationVI subjects will be studied before the implant is activated (pre) and then after it is turned on (acute On); this will take about 2 hrs. Then they will have 8 hours of motion-modulated VI stimulation while they actively explore the hospital environment, after studies will be repeated (chronic On). Each set of outcome experiments will be performed twice, once with and once without low-levels of stochastic noise added to the VI stimulation provided for the 8-hour period. The noise amplitude is tailored to each patient to maximize stochastic resonance so extraction \& integration of spatial signal provided by the VI will always be the first experiment, but the order of the subsequent outcome sessions (active/passive head rotations, tilt/translation motion discrimination and VOR behavioral changes \& postural control) will be randomized. VI subjects will participate in 4 full-day sessions, each separated by at least a month. | Device | Vestibular & Cochlear Implant Patients |
Primary outcome
Changes in Postural Sway Thresholds
Time frame: 3 days
Changes in threshold for postural sway, measured using IMUs (inertial measurement unit) placed on the upper back, head, and torso, will be assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following motion-modulated stimulation.
Changes in Postural Sway Amplitudes
Time frame: 3 days
Changes in amplitude in postural sway, measured using IMUs (inertial measurement unit) placed on the upper back, head, and torso, will be assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following motion-modulated stimulation.
Changes in Gait dynamics
Time frame: 3 days
Changes in gait dynamics, measured using IMUs (inertial measurement unit) placed on the upper back, head, each ankle, and torso during various physical therapy walking tasks (Functional Gait Analysis), will be assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following motion-modulated stimulation.
Changes in Vestibular Ocular Reflex (VOR) Amplitude
Time frame: 3 days
This reflex which moves the eyes in response to head movement and is driven by the sensors in the inner ear. Participants will walk in place while fixating on a cyclopean eye-centered near target (0.5m) and a far target (10m) for 60sec each. A lightweight infrared eye tracker with built in 6 degree of freedom IMU (eyeseecam) will be used to measure eye and head movements together. The amplitude or 'gain' (eye velocity divided by head velocity) is assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. Low gain is associated with impaired VOR.
Changes in Vestibular Ocular Reflex (VOR) Threshold
Time frame: 3 days
This reflex which moves the eyes in response to head movement and is driven by the sensors in the inner ear. Participants will wear a lightweight infrared eye tracker with built in 6 degree of freedom IMU (eyeseecam). Investigators will gently rotate the participant about the yaw-axis while measuring eye and head movements together. The velocity threshold for VOR is quantified before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following motion-modulated stimulation.
Changes in motion perception in yaw
Time frame: 3 days
Perception of head motion and orientation relative to gravity is measured by a continuous task during yaw rotation where the goal is to keep a light pointing in the direction of the start position/straight ahead. The task requires constant corrections because the light's orientation shifts randomly (based on integrated Brownian noise) and accelerates when a wheel is turned, resulting in overshooting errors. This method, a variant of the Critical Control Task used in humans, is an accurate way to capture perceived head motion. Motion perception during yaw-rotation will be assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation.
Changes in motion perception orientation in roll
Time frame: 3 days
Perception of head motion and orientation relative to gravity is measured by a continuous subjective-visual-vertical (SVV) task where the subject uses a small steering wheel to keep a light bar orientated parallel to the perceived earth-vertical. The task requires constant corrections because the light bar's orientation shifts randomly (based on integrated Brownian noise) and accelerates when the wheel is turned, resulting in overshooting errors. This method, a variant of the Critical Control Task used in humans, is an accurate way to capture perceived head orientation. The 'perceived upright' is assessed before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation.
Changes in angular error during a navigation task
Time frame: 3 days
Participants will perform a path integration or 'complete the triangle' virtual reality task - angular error of responses is measured before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. Greater angular error and variability of angular error is associated with worse visual-spatial memory.
changes in dizziness handicap index score
Time frame: 3 days
Participants will fill out the dizziness handicap index questionnaire before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. It is scored 0 to 100 with high scores indicating greater subjective dizziness and disbalance.
changes in activities-specific balance confidence score
Time frame: 3 days
Participants will fill out the activities-specific balance confidence questionnaire before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. It is scored from 0-100% with lower scores showing less confidence in balance and more subjective dizziness.
changes in oscillopsia functional impact scale score
Time frame: 3 days
Participants will fill out the oscillopsia functional impact scale before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. It is scored from 0 to 215 in 5 point increments.
changes in reported quality of life
Time frame: 3 days
Quality of life will be assessed by participants filling out the short form-36 health survey (scored 0 to 100 points) before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation.
changes in cognitive impairment - visual-spatial function
Time frame: 3 days
Cognitive impairment will be assessed by participants completing a neuropsychological test battery with a focus on visual-spatial tasks before prosthetic stimulation, immediately after the prosthesis is activated, and daily for 3 days following 8hrs of motion-modulated stimulation. More errors and time to complete the tasks in the battery are associated with visual-spatial memory and function impairment.
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2024.
Related trials for Vestibular Disorder
Not yet recruitingPhase 2
Selumetinib for NF2-Related Schwannomatosis
Neurofibromatosis Type 2, NF2
RecruitingPhase 2
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Neurofibromatosis Type 2, Vestibular Schwannoma
Recruiting
Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device
Hearing Loss, Dizziness
RecruitingPhase 3
Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients
Vestibular Schwannoma, Facial Nerve Paralysis
Recruiting
Mapping of Vestibular Centers Activation Using fMRI in Patients With Vestibular Schwannoma
Vestibular Schwannoma, Unilateral Vestibular Deficit
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vestibular prosthesis/implant and Vestibular Implant Stimulation in people with Vestibular Disorder and Vestibular Ataxia, run by Massachusetts Eye and Ear Infirmary at 3 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 1 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States, Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in Postural Sway Thresholds (time frame: 3 days). The study lists 13 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2024.